Search results for "target"

showing 10 items of 1196 documents

Allergic contact dermatitis: understanding the immune response and potential for targeted therapy using cytokines.

1997

Allergic contact dermatitis is the most common job-related disease of the western world. The only available treatments are avoidance of contact with the allergen and the use of potent corticosteroids. Recently, the role of cytokines in the pathogenesis of this disease has been studied and, besides defining the key molecules and basic cellular immune responses responsible for disease development, these studies might help to develop new therapeutic strategies to target cytokines and thereby try to alter or abrogate ongoing immune reactions.

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT-LymphocytesDiseaseCD8-Positive T-Lymphocytesmedicine.disease_causeLymphocyte ActivationTargeted therapyPathogenesisMiceImmune systemAllergenGeneticsmedicineAnimalsHumansRNA AntisenseAllergic contact dermatitisbusiness.industryDendritic CellsGenetic Therapymedicine.diseaseLangerhans CellsImmunologyDermatitis Allergic ContactMolecular MedicineCytokinesImmune reactionbusinessMolecular medicine today
researchProduct

Transverse-momentum-dependent Multiplicities of Charged Hadrons in Muon-Deuteron Deep Inelastic Scattering

2017

A semi-inclusive measurement of charged hadron multiplicities in deep inelastic muon scattering off an isoscalar target was performed using data collected by the COMPASS Collaboration at CERN. The following kinematic domain is covered by the data: photon virtuality $Q^{2}>1$ (GeV/$c$)$^2$, invariant mass of the hadronic system $W > 5$ GeV/$c^2$, Bjorken scaling variable in the range $0.003 < x < 0.4$, fraction of the virtual photon energy carried by the hadron in the range $0.2 < z < 0.8$, square of the hadron transverse momentum with respect to the virtual photon direction in the range 0.02 (GeV/$c)^2 < P_{\rm{hT}}^{2} < 3$ (GeV/$c$)$^2$. The multiplicities are pres…

CERN LabComputerSystemsOrganization_COMPUTERSYSTEMIMPLEMENTATIONMULTIPLICITIESdimension: 3PT DEPENDENTComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONFOS: Physical sciencesComputerApplications_COMPUTERSINOTHERSYSTEMStarget: isoscalarmuon deuteron: deep inelastic scattering[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]nucl-extransverse momentum dependencehadron: transverse momentumSIDISCOMPASSGeneralLiterature_MISCELLANEOUSHigh Energy Physics - Experimentscaling: BjorkenSubatomär fysikcharged particle: multiplicityHigh Energy Physics - Experiment (hep-ex)[ PHYS.HEXP ] Physics [physics]/High Energy Physics - Experiment [hep-ex]mass: hadronicSubatomic Physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear Physics - Experiment[ PHYS.NEXP ] Physics [physics]/Nuclear Experiment [nucl-ex]Nuclear Experiment (nucl-ex)quantum chromodynamics: perturbation theoryNuclear ExperimentNuclear ExperimentDIShep-exhadron: multiplicityeffect: nonperturbativeperturbation theory: higher-orderCERN SPSphoton: energysemi-inclusive reactionComputingMethodologies_PATTERNRECOGNITIONkinematicsDIS; SIDIS; MULTIPLICITIES; PT DEPENDENTHigh Energy Physics::ExperimentParticle Physics - Experimentexperimental resultsphoton: virtual
researchProduct

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological c…

2022

Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates…

Cancer Research:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES]Lung NeoplasmsTesting:Biological Factors::Biomarkers [CHEMICALS AND DRUGS]:factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS]Targeted therapiesPulmons - Càncer:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES]Carcinoma Non-Small-Cell LungProto-Oncogene ProteinsGeneticsBiomarkers TumorHumansProspective StudiesCàncerDemographyReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesErbB ReceptorsOncologySpainPulmonsMarcadors bioquímicsBiomarkersMetastatic lung cancer
researchProduct

Inhibition of HSP70: a challenging anti-cancer strategy.

2012

HSP70 is a chaperone that accumulates in the cells after many different stresses promoting cell survival in response to the adverse conditions. In contrast to normal cells, most cancer cells abundantly express HSP70 at the basal level to resist to various insults at different stages of tumorigenesis and during anti-cancer treatment. This cancer cells addiction for HSP70 is the rational for its targeting in cancer therapy. Much effort has been dedicated in the last years for the active search of HSP70 inhibitors. Additionally, the recent clinical trials on highly promising inhibitors of another stress protein, HSP90, showed compensatory increase in HSP70 levels and raised the question of nec…

Cancer ResearchAntineoplastic AgentsApoptosismedicine.disease_cause03 medical and health sciences0302 clinical medicineImmune systemStress PhysiologicalHeat shock proteinNeoplasmsmedicineAutophagyAnimalsHumansHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsMolecular Targeted Therapy030304 developmental biology0303 health sciencesbiologyHsp903. Good healthNeoplasm ProteinsProtein Structure TertiaryClinical trialOncologyApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisChaperone (protein)Drug DesignCancer cellImmunologybiology.proteinCancer researchDrug Screening Assays AntitumorCarcinogenesisMolecular ChaperonesCancer letters
researchProduct

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

2015

Goodson, William H. et al.

Cancer ResearchCarcinogenesis[SDV]Life Sciences [q-bio]METHOXYCHLOR-INDUCED ALTERATIONSReviewPharmacologyMESH: Carcinogens EnvironmentalCarcinogenic synergiesChemical mixturesNeoplasmsMESH: AnimalsMESH: NeoplasmsCarcinogenesiRisk assessmentCancerACTIVATED PROTEIN-KINASESMedicine (all)Low dose1. No povertyCumulative effectsBREAST-CANCER CELLSGeneral MedicineEnvironmental exposureMESH: CarcinogenesisBIO/10 - BIOCHIMICAEPITHELIAL-MESENCHYMAL TRANSITION3. Good health[SDV] Life Sciences [q-bio]Environmental CarcinogenesisESTROGEN-RECEPTOR-ALPHARisk assessmentHumanMESH: Environmental ExposureENDOCRINE-DISRUPTING CHEMICALSTARGETING TISSUE FACTOR[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPrototypical chemical disruptorsExposure[SDV.CAN] Life Sciences [q-bio]/CancerEnvironmental healthmedicine[SDV.EE.SANT] Life Sciences [q-bio]/Ecology environment/HealthCarcinogenEnvironmental carcinogenesis[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthMESH: HumansAnimalPOLYBROMINATED DIPHENYL ETHERSCancerEnvironmental Exposuremedicine.diseaseMESH: Hazardous SubstancesCarcinogens EnvironmentalMIGRATION INHIBITORY FACTORVASCULAR ENDOTHELIAL-CELLSHazardous SubstanceNeoplasmCarcinogenesis
researchProduct

Cyclin dependent kinase-1 (Cdk-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (pdac)

2021

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans, due to late diagnosis and limited treatment possibilities. Improved treatment for PDAC patients is warranted. Cyclin-dependent kinase 1 (CDK1) is a stimulator of cell cycle progression and its activity is regularly enhanced in pancreatic cancer cells. Therefore, CDK1 has been proposed as a novel drug target to treat patients with PDAC. This review describes the potential of CDK1 inhibition as a treatment for PDAC by outlining the molecular pathways influenced by CDK1 inhibition and new therapeutic strategies. Abstract The role of CDK1 in PDAC onset and development is two-fold. Firstly, since …

Cancer ResearchCell cycle checkpointendocrine system diseasesmedicine.medical_treatmentReviewenvironment and public healthTargeted therapyCyclin-dependent kinaseCancer stem cellPancreatic cancermedicineNovel treatmentCDK1 inhibitionRC254-282Cyclin-dependent kinase 1biologyChemistryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPDACPancreatic cancerCell cyclemedicine.diseaseenzymes and coenzymes (carbohydrates)Oncologybiology.proteinCancer researchStem cellbiological phenomena cell phenomena and immunityCell cycle regulation
researchProduct

A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing

2002

We describe here the definition and characterization of antigen CT-8/HOM-TES-85 encoded by a previously unknown gene and identified by serological expression screening using antibodies from a seminoma patient. Intriguingly, the leucine zipper region of CT-8/HOM-TES-85 shows an atypical amphipathy with clusters of hydrophobic residues that is exclusively shared by the N-myc proto-oncogene. CT-8/HOM-TES-85 gene is tightly silenced in normal tissues except for testis. However, it is frequently activated in human neoplasms of different types including lung cancer, ovarian cancer, melanoma and glioma. Endogenous as well as heterogeneously expressed CT-8/HOM-TES-85 targets predominantly to the nu…

Cancer ResearchLeucine zipperDNA ComplementaryTranscription GeneticGreen Fluorescent ProteinsImmunoblottingBiologymedicine.disease_causeModels BiologicalProto-Oncogene MasAntigens NeoplasmTranscription (biology)Protein targetingTumor Cells CulturedGeneticsmedicineHumansTissue DistributionAntigensMolecular BiologyGeneLeucine ZippersATF3GenomeReverse Transcriptase Polymerase Chain ReactionAlternative splicingfood and beveragesBlotting NorthernPhenotypeProtein Structure TertiaryDNA-Binding ProteinsAlternative SplicingLuminescent ProteinsPhenotypeMicroscopy FluorescenceModels ChemicalRNA splicingCancer researchOncogene
researchProduct

Myeloid cell heterogeneity in lung cancer: implication for immunotherapy

2020

Lung is a specialized tissue where metastases from primary lung tumors takeoff and those originating from extra-pulmonary sites land. One commonality characterizing these processes is the supportive role exerted by myeloid cells, particularly neutrophils, whose recruitment is facilitated in this tissue microenvironment. Indeed, neutrophils have important part in the pathophysiology of this organ and the key mechanisms regulating neutrophil expansion and recruitment during infection can be co-opted by tumor cells to promote growth and metastasis. Although neutrophils dominate the myeloid landscape of lung cancer other populations including macrophages, dendritic cells, mast cells, basophils …

Cancer ResearchLung NeoplasmsMyeloidmedicine.medical_treatmentImmunologyCellGene ExpressionContext (language use)ReviewSettore MED/08 - Anatomia PatologicaBiologyMetastasis03 medical and health sciences0302 clinical medicineImmune systemBiomarkers TumormedicineAnimalsHumansImmunology and AllergyMolecular Targeted TherapyDNA-based trapsLung cancerLung cancer · Myeloid cells · DNA-based traps · ImmunotherapyLungDisease ManagementImmunotherapymedicine.diseaseImmunohistochemistrymedicine.anatomical_structureOncologyMyeloid cellsCancer researchDisease SusceptibilityImmunotherapyLung cancerBiomarkers030215 immunologyCancer Immunology, Immunotherapy
researchProduct

Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors.

2001

The DNA-repair protein O6-methylguanine-DNA methyltransferase (MGMT) is a decisive determinant of resistance of tumor cells to methylating and chloroethylating anti-cancer drugs. Therefore, selective inhibition of MGMT in tumors is expected to cause tumor sensitization. Several inhibitors of MGMT have been developed which function in both tumors and normal tissue. To deplete MGMT preferentially in tumors, strategies to target the inhibitor to the tumor tissue need to be developed. Here, we report on the properties of glucose-conjugated MGMT inhibitors that might be useful for tumor targeting since tumor cells frequently over-express glucose transporter. O6-Benzylguanine (O6BG), 8-aza-O6-ben…

Cancer ResearchMethyltransferaseGuaninebiologyDNA repairGlucose transporterbiology.organism_classificationDNA methyltransferaseMolecular biologydigestive system diseasesHeLaO(6)-Methylguanine-DNA MethyltransferaseGlucoseOncologyTargeted drug deliveryEnzyme inhibitorbiology.proteinTumor Cells CulturedHumansEnzyme InhibitorsneoplasmsAlkyltransferaseHeLa CellsInternational journal of cancer
researchProduct

Nanofitins targeting heat shock protein 110: an innovative immunotherapeutic modality in cancer.

2021

The presence of an inactivating heat shock protein 110 (HSP110) mutation in colorectal cancers has been correlated with an excellent prognosis and with the ability of HSP110 to favor the formation of tolerogenic (M2-like) macrophages. These clinical and experimental results suggest a potentially powerful new strategy against colorectal cancer: the inhibition of HSP110. In this work, as an alternative to neutralizing antibodies, Nanofitins (scaffold ~7 kDa proteins) targeting HSP110 were isolated from the screening of a synthetic Nanofitin library, and their capacity to bind (immunoprecipitation, biolayer interferometry) and to inhibit HSP110 was analyzed in vitro and in vivo. Three Nanofiti…

Cancer ResearchMice03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemPeptide LibraryIn vivoCell Line TumorHeat shock proteinTumor MicroenvironmentmedicineAnimalsHumansCytotoxic T cellHSP110 Heat-Shock Proteinssmall peptide moleculesTumor microenvironmentanticancer targeted therapybiologyChemistryMacrophagesCancer[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseXenograft Model Antitumor AssaysPeptide FragmentsIn vitro3. Good healthNanofitinsOncologyPositron-Emission Tomography030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleAntibodyColorectal NeoplasmsHSP110
researchProduct